DexCom Future Growth
Future criteria checks 2/6
DexCom is forecast to grow earnings and revenue by 15.4% and 10.6% per annum respectively. EPS is expected to grow by 14% per annum. Return on equity is forecast to be 30.5% in 3 years.
Key information
15.4%
Earnings growth rate
14.04%
EPS growth rate
| Medical Equipment earnings growth | 15.6% |
| Revenue growth rate | 10.6% |
| Future return on equity | 30.50% |
| Analyst coverage | Good |
| Last updated | 02 May 2026 |
Recent future growth updates
Recent updates
Type 2 Coverage Expansion And AI Features Will Shape A Balanced Long Term Outlook
Catalysts About DexCom DexCom develops and sells continuous glucose monitoring systems used by people with diabetes around the world. What are the underlying business or industry changes driving this perspective?
DXCM: AI Coaching And Share Repurchases Will Support Future Healthcare Momentum
Analysts have made a small trim to DexCom's implied value, cutting the analyst price target by about $0.25, as they balance slightly softer modeled growth and margins with generally supportive recent research, including multiple target increases following the latest medtech sector updates. Analyst Commentary Recent research on DexCom reflects a mix of optimism and caution as analysts adjust their models and targets across the medtech group.DXCM: AI Coaching And Buybacks Will Support Future Healthcare Momentum
Analysts have nudged DexCom's fair value estimate higher to $87.13 from $86.12, citing a series of upward price target revisions that cluster around the low to mid $80s, while one firm maintains a more cautious view focused on rising competition. Analyst Commentary Recent research on DexCom reflects a split view, with several bullish analysts lifting price targets into the low to mid US$80s, while at least one bearish voice is positioning closer to the low US$70s.DXCM: AI Coaching And Buybacks Will Support Future Market Share Confidence
DexCom's fair value estimate edges up by about $0.27 as analysts fine tune assumptions on the discount rate, revenue growth, profit margin, and future P/E, following a mix of price target changes across the Street, including recent upward revisions toward $84 to $86 and a lower $71 target tied to competition concerns. Analyst Commentary Recent Street research on DexCom reflects a split view, with some firms nudging targets higher into the mid $80s and others pushing back toward the low $70s on competition concerns.DXCM: AI Coaching And Share Repurchases Will Support Long-Term Confidence
DexCom's intrinsic value estimate nudged higher to $85.85, with analysts modestly lifting price targets, often in the $1 to $12 range, as they weigh recent target increases against a Barclays downgrade that highlights rising competitive pressure in continuous glucose monitoring. Analyst Commentary Recent research on DexCom reflects a split tape, with several firms adjusting price targets higher by amounts in the low single digits to low teens, while one major firm has moved to a more cautious stance with a lower target and an Underweight rating.DXCM: Medicare Support And AI Coaching Rollout Will Sustain Long-Term Confidence
Our updated DexCom narrative reflects a small increase in fair value to $85.46. Analysts point to a mix of modestly lower assumed revenue growth, slightly higher profit margin expectations, a reduced future P/E multiple, and a series of recent price target adjustments that are mostly higher in dollar terms despite some concerns around rising competition.The Strong Earnings Posted By DexCom (NASDAQ:DXCM) Are A Good Indication Of The Strength Of The Business
Feb 19
DXCM: Medicare Support And AI Coaching Features Will Sustain Long-Term Confidence
Analysts made only a slight upward tweak to the DexCom price target to about US$85, reflecting small adjustments to their growth, margin and P/E assumptions as they balance caution on rising competition with support from recent positive research updates. Analyst Commentary Recent research on DexCom reflects a split view, with some analysts highlighting supportive policy signals and valuation upside, while others focus on intensifying competition and reduced price targets.DXCM: Medicare Support And 2026 Sensor Expansion Will Sustain Long-Term Confidence
Our DexCom price target edges down to about $85 from $85.27, reflecting slightly lower assumed profit margins and P/E multiple, partly offset by analysts citing supportive Medicare reimbursement commentary and mixed Street views on competition, valuation, and 2026 guidance. Analyst Commentary Recent research on DexCom highlights a clear split between bullish and bearish analysts, with views clustering around competition, execution on guidance, and how much investors are willing to pay for the stock through the P/E multiple.DXCM: Medicare Support And New Sensor Duration Will Sustain Long-Term Confidence
Analysts nudged their fair value estimate for DexCom slightly higher to about $85 per share, citing a generally supportive regulatory backdrop for continuous glucose monitors and noting that recent price target cuts still reflect confidence in the company’s long term patient growth and product profile. Analyst Commentary Recent research updates on DexCom highlight a mix of optimism around the core continuous glucose monitor franchise and caution around guidance, pricing, and execution into 2026.DXCM: Medicare Reimbursement Stability Will Support Confidence Despite Emerging Legal And Safety Headlines
Analysts have nudged our DexCom fair value estimate slightly higher, from $84.31 to $84.85, as they balance recent price target cuts with continued Buy and Outperform ratings that point to resilient growth, stable margins, and a favorable regulatory and product backdrop. Analyst Commentary Street research continues to reflect a constructive long term view on DexCom, even as recent reports incorporate more conservative assumptions and lower base case price targets.DXCM: Medicare Payment Developments Will Drive Confidence Despite Recent Short-Term Weakness
DexCom's analyst price target has decreased modestly to approximately $84.31 from $84.96, as analysts cite a mix of positive Medicare policy developments and tempered optimism following company guidance updates and recent survey data. Analyst Commentary Recent analyst research on DexCom reflects both optimism about the company's long-term prospects and concerns regarding near-term execution and growth trends.DXCM: Share Recovery Likely With Positive Setup Expected For 2026
Analysts have lowered their price targets for DexCom, reducing the fair value estimate from $98.40 to $84.96. This reflects a reaction to recent conservative guidance, weaker growth outlook, and updated margin expectations.Earnings Beat: DexCom, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Nov 02DXCM: Expanding Reimbursement Will Drive Gains Despite Market Uncertainty
The consensus analyst price target for DexCom was recently lowered, with the average fair value estimate moving down by less than $1 to approximately $98.40. Analysts cite investor concerns around the company’s conservative guidance and gross margin pressure, but remain generally positive on long-term growth and patient retention trends.Insurance Reimbursement And Digital Health Integration Will Unlock Global Potential
DexCom's average analyst price target has decreased by approximately $1.58 to around $98.96. Analysts are recalibrating their outlook in light of mixed survey results and a shift in assumptions around reimbursement trends and profitability expectations.DexCom May Be The Most Underrated Growth Story In Healthcare
Oct 06Insurance Reimbursement And Digital Health Integration Will Unlock Global Potential
Analysts have modestly reduced DexCom's fair value estimate by approximately $1.54 to $100.54 per share. This change reflects slightly lower revenue growth projections and recent adjustments in price targets based on mixed survey data and evolving reimbursement trends.We Think DexCom (NASDAQ:DXCM) Can Manage Its Debt With Ease
Jul 22DexCom's (NASDAQ:DXCM) Returns On Capital Are Heading Higher
Jul 09Is DexCom, Inc. (NASDAQ:DXCM) Trading At A 24% Discount?
May 16DexCom: Valuation Does Not Factor In Slowing Growth
Mar 04DexCom: Fairly Priced In 2025; Why I'm Not Expecting A Share Price Comeback
Jan 17DexCom: Brighter 2025 From Stelo Ramp
Dec 10DexCom Growing Into Its Valuation, But Still No Bargain
Oct 25DexCom Q3 Preview: Walking On Eggshells With Its Channel Relationships
Oct 16DexCom: Investors Discounting Long CGM Growth Runway
Sep 19DexCom Q2 Earnings: Traditional Market Overreaction
Aug 07Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2028 | 6,535 | 1,416 | 1,599 | 2,059 | 18 |
| 12/31/2027 | 5,849 | 1,160 | 1,259 | 1,737 | 25 |
| 12/31/2026 | 5,227 | 961 | 993 | 1,448 | 25 |
| 3/31/2026 | 4,818 | 930 | 1,429 | 1,783 | N/A |
| 12/31/2025 | 4,662 | 836 | 1,077 | 1,441 | N/A |
| 9/30/2025 | 4,516 | 721 | 1,062 | 1,448 | N/A |
| 6/30/2025 | 4,301 | 572 | 571 | 988 | N/A |
| 3/31/2025 | 4,148 | 535 | 575 | 964 | N/A |
| 12/31/2024 | 4,033 | 576 | 631 | 990 | N/A |
| 9/30/2024 | 3,954 | 681 | 535 | 822 | N/A |
| 6/30/2024 | 3,935 | 667 | 666 | 891 | N/A |
| 3/31/2024 | 3,802 | 639 | 584 | 802 | N/A |
| 12/31/2023 | 3,622 | 542 | 512 | 749 | N/A |
| 9/30/2023 | 3,403 | 377 | 500 | 747 | N/A |
| 6/30/2023 | 3,198 | 358 | 466 | 771 | N/A |
| 3/31/2023 | 3,023 | 293 | 416 | 754 | N/A |
| 12/31/2022 | 2,910 | 341 | 305 | 670 | N/A |
| 9/30/2022 | 2,793 | 244 | 261 | 643 | N/A |
| 6/30/2022 | 2,673 | 230 | 216 | 597 | N/A |
| 3/31/2022 | 2,572 | 258 | 95 | 486 | N/A |
| 12/31/2021 | 2,449 | 217 | 53 | 443 | N/A |
| 9/30/2021 | 2,319 | 577 | 140 | 509 | N/A |
| 6/30/2021 | 2,170 | 562 | 101 | 409 | N/A |
| 3/31/2021 | 2,027 | 530 | 236 | 502 | N/A |
| 12/31/2020 | 1,927 | 550 | 277 | 476 | N/A |
| 9/30/2020 | 1,821 | 231 | 264 | 447 | N/A |
| 6/30/2020 | 1,716 | 205 | 209 | 394 | N/A |
| 3/31/2020 | 1,601 | 148 | 131 | 305 | N/A |
| 12/31/2019 | 1,476 | 101 | N/A | 315 | N/A |
| 9/30/2019 | 1,351 | -171 | N/A | 205 | N/A |
| 6/30/2019 | 1,222 | -170 | N/A | 167 | N/A |
| 3/31/2019 | 1,128 | -130 | N/A | 144 | N/A |
| 12/31/2018 | 1,032 | -127 | N/A | 123 | N/A |
| 9/30/2018 | 915 | 43 | N/A | 131 | N/A |
| 6/30/2018 | 833 | -5 | N/A | 110 | N/A |
| 3/31/2018 | 761 | -33 | N/A | 83 | N/A |
| 12/31/2017 | 719 | -50 | N/A | 92 | N/A |
| 9/30/2017 | 669 | -48 | N/A | 64 | N/A |
| 6/30/2017 | 633 | -65 | N/A | 51 | N/A |
| 3/31/2017 | 599 | -88 | N/A | 57 | N/A |
| 12/31/2016 | 573 | -66 | N/A | 56 | N/A |
| 9/30/2016 | 533 | -57 | N/A | 54 | N/A |
| 6/30/2016 | 490 | -80 | N/A | 49 | N/A |
| 3/31/2016 | 445 | -64 | N/A | 45 | N/A |
| 12/31/2015 | 402 | -58 | N/A | 49 | N/A |
| 9/30/2015 | 356 | -58 | N/A | 46 | N/A |
| 6/30/2015 | 319 | -20 | N/A | 40 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DXCM's forecast earnings growth (15.4% per year) is above the savings rate (3.4%).
Earnings vs Market: DXCM's earnings (15.4% per year) are forecast to grow slower than the US market (15.8% per year).
High Growth Earnings: DXCM's earnings are forecast to grow, but not significantly.
Revenue vs Market: DXCM's revenue (10.6% per year) is forecast to grow slower than the US market (11.1% per year).
High Growth Revenue: DXCM's revenue (10.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DXCM's Return on Equity is forecast to be high in 3 years time (30.5%)
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/03 01:28 |
| End of Day Share Price | 2026/05/01 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DexCom, Inc. is covered by 52 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jeffrey Johnson | Baird |
| Travis Steed | Barclays |
| Matthew Miksic | Barclays |